Showing 1 - 20 results of 40 for search 'Andreas Engert', query time: 0.04s
Refine Results
-
1
The First Year of HemaSphere and Many More to Come by Andreas Engert, Jan Cools
Published 2018-12-01
Article -
2
The Fifth Year of HemaSphere by Jan Cools, Andreas Engert
Published 2021-06-01
Article -
3
THERAPY-RELATED MYELOID NEOPLASMS IN PATIENTS TREATED FOR HODGKIN LYMPHOMA by Dennis A Eichenauer, Andreas Engert
Published 2011-10-01
Article -
4
The Updated European Hematology Association Research Roadmap by Andreas Engert, Francesco Cerisoli, Jan Cools
Published 2022-06-01
Article -
5
Introducing the HemaSphere Controversies Series by Dennis A. Eichenauer, Jan Cools, Andreas Engert
Published 2019-10-01
Article -
6
Open Access is the Plan S Way Forward in Hematology Research by Jan Cools, Andreas Engert, John Gribben, Elizabeth Macintyre
Published 2020-02-01
Article -
7
THE CHEMOKINE CCL17/TARC AS A BIOMARKER IN HODGKIN LYMPHOMA by Maike Sauer, Sabine Ponader, Andreas Engert, Elke Pogge von Strandmann
Published 2013-08-01
Article -
8
-
9
-
10
Controversies in the Treatment of Classical Hodgkin Lymphoma by Dennis A. Eichenauer, Marc André, Peter Johnson, Alexander Fossa, Olivier Casasnovas, Andreas Engert
Published 2018-10-01
Article -
11
-
12
P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial by Paul J. Bröckelmann, Helen Kaul, Michael Fuchs, Carsten Kobe, Christian Baues, Peter Borchmann, Andreas Engert
Published 2022-10-01
Article -
13
P038: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma by Berit Müller-Meinhard, Sarah Reinke, Nicole Seifert, Andreas Engert, Paul J. Bröckelmann, Michael Altenbuchinger, Wolfram Klapper
Published 2022-10-01
Article -
14
Suicide in European Hodgkin Lymphoma Patients by Austin I. Kim, Helen Goergen, Andreas Engert, Ann S. LaCasce, Louise Maranda, Bruce Barton, Sven Borchmann
Published 2019-04-01
Article -
15
-
16
The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered by Peter Borchmann, Alexander Fosså, Monika Długosz-Danecka, Boris Böll, Markus Dietlein, Carsten Kobe, Helen Goergen, Andreas Engert
Published 2018-06-01
Article -
17
P039: HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma by Johanna Grund, Sarah Reinke, Annette Plütschow, Bastian Von Tresckow, Peter Borchmann, Andreas Engert, Paul J. Bröckelmann, Wolfram Klapper
Published 2022-10-01
Article -
18
P049: Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma by Nicole Seifert, Sarah Reinke, Johanna Grund, Berit Müller-Meinhard, Andreas Engert, Paul J. Bröckelmann, Wolfram Klapper, Michael Altenbuchinger
Published 2022-10-01
Article -
19
Proton versus photon deep inspiration breath hold technique in patients with hodgkin lymphoma and mediastinal radiation by Christian Baues, Simone Marnitz, Andreas Engert, Wolfgang Baus, Karolina Jablonska, Antonella Fogliata, Andrés Vásquez-Torres, Marta Scorsetti, Luca Cozzi
Published 2018-07-01
Article -
20
Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma – Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center by Jesko Momotow, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Sven Borchmann, Bastian v. Tresckow, Carsten Kobe, Andreas Engert, Stephanie Sasse
Published 2019-10-01
Article